Alligamycin A, an antifungal β-lactone spiroketal macrolide from Streptomyces iranensis

Zhijie Yang, Yijun Qiao, Emil Strøbech, Jens Preben Morth, Grit Walther, Tue Sparholt Jørgensen, Kah Yean Lum, Gundela Peschel, Miriam A. Rosenbaum, Viola Previtali, Mads Hartvig Clausen, Marie Vestergaard Lukassen, Charlotte Held Gotfredsen, Oliver Kurzai, Tilmann Weber and Ling Ding ()
Additional contact information
Zhijie Yang: Technical University of Denmark
Yijun Qiao: Technical University of Denmark
Emil Strøbech: Technical University of Denmark
Jens Preben Morth: Technical University of Denmark
Grit Walther: Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute
Tue Sparholt Jørgensen: Technical University of Denmark
Kah Yean Lum: Technical University of Denmark
Gundela Peschel: Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute
Miriam A. Rosenbaum: Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute
Viola Previtali: Technical University of Denmark
Mads Hartvig Clausen: Technical University of Denmark
Marie Vestergaard Lukassen: Technical University of Denmark
Charlotte Held Gotfredsen: Technical University of Denmark
Oliver Kurzai: Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute
Tilmann Weber: Technical University of Denmark
Ling Ding: Technical University of Denmark

Nature Communications, 2024, vol. 15, issue 1, 1-12

Abstract: Abstract Fungal infections pose a great threat to public health and there are only four main types of antifungal drugs, which are often limited with toxicity, drug-drug interactions and antibiotic resistance. Streptomyces is an important source of antibiotics, represented by the clinical drug amphotericin B. Here we report the discovery of alligamycin A (1) as an antifungal compound from the rapamycin-producer Streptomyces iranensis through genome-mining, genetics and natural product chemistry approaches. Alligamycin A harbors a unique chemical scaffold with 13 chiral centers, featuring a β-lactone moiety, a [6,6]-spiroketal ring, and an unreported 7-oxo-octylmalonyl-CoA extender unit incorporated by a potential crotonyl-CoA carboxylase/reductase. It is biosynthesized by a type I polyketide synthase which is confirmed through CRISPR-based gene editing. Alligamycin A displayed potent antifungal effects against numerous clinically relevant filamentous fungi, including resistant Aspergillus and Talaromyces species. β-Lactone ring is essential for the antifungal activity since alligamycin B (2) with disruption in the ring abolished the antifungal effect. Proteomics analysis revealed alligamycin A potentially disrupts the integrity of fungal cell walls and induces the expression of stress-response proteins in Aspergillus niger. Discovery of the potent antifungal candidate alligamycin A expands the limited antifungal chemical space.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53695-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53695-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53695-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().